研报掘金丨华源证券：首予新和成“买入”评级，结构升级，韧性十足

Group 1 - The core viewpoint of the report indicates that Xinhecheng's product line is continuously expanding, demonstrating strong performance resilience [1] - Methionine is experiencing rapid growth with significant cost advantages, supported by a global demand increase of approximately 4-6% annually, translating to an additional demand of about 100,000 tons per year [1] - The supply of methionine is concentrated, with major players like Evonik and Adisseo holding over 80% of the market share, while aging facilities and rising costs are causing a decline in market share for overseas leaders [1] Group 2 - Xinhecheng's current production capacity stands at 550,000 tons, placing it among the top global producers, with net profit margins projected at 35% for 2024 and 38.3% for the first half of 2025 [1] - The flavoring segment shows strong profitability and stable growth, while new materials are expected to grow rapidly [1] - Recent price stabilization and recovery for vitamins and methionine are driven by seasonal demand and anti-involution policies [1] Group 3 - Comparable companies include Adisseo, Zhejiang Medicine, and Kingenta, with Xinhecheng being recognized as a leading player in fine chemicals, possessing both pricing elasticity for products and growth potential in new materials [1] - The report initiates coverage with a "Buy" rating based on these factors [1]